Medullary thyroid carcinoma (MTC) is a rare tumour that represents 5--10% of all types of thyroid cancer, and accounts for a disproportionate number of thyroid cancer deaths ([Hundahl *et al*, 1998](#bib17){ref-type="other"}). Except for surgery, therapy for MTC is generally ineffective. MTC may occur sporadically (in about 75% of cases) or as a part of the autosomal dominantly inherited cancer syndrome, known as multiple endocrine neoplasia type 2 (MEN 2) ([Mulligan *et al*, 1993](#bib27){ref-type="other"}; [Eng, 1999](#bib12){ref-type="other"}; [Frank-Raue *et al*, 2007](#bib14){ref-type="other"}). MTC is the most common cause of death in patients with MEN 2 ([Skinner *et al*, 2005](#bib35){ref-type="other"}). This familial type of thyroid carcinoma usually originates as multifocal C-cell hyperplasia, its progression to MTC is extremely variable, and may take several years ([Carling, 2005](#bib6){ref-type="other"}). In sporadic cases, the mean age at presentation is 50 years, with a slight female predominance ([Matias-Guiu *et al*, 2004](#bib26){ref-type="other"}).

Activating germline mutations in the *RE*arranged during *T*ransfection (*RET*) gene are detected in over 95% of MEN 2 cases ([Mulligan *et al*, 1993](#bib27){ref-type="other"}; [Marx, 2005](#bib25){ref-type="other"}). The oncogenic potential of different *RET* mutations seems to be dependent on the site of the amino acid change, and may account for the diverse phenotypes observed in MEN 2 patients ([Asai *et al*, 1995](#bib2){ref-type="other"}).

The screening of *RET* mutations has been carried out in different series of sporadic MTC, however the observed frequencies are variable (12--100%) ([Hofstra *et al*, 1994](#bib16){ref-type="other"}; [Zedenius *et al*, 1994](#bib41){ref-type="other"}; [Jhiang *et al*, 1996](#bib19){ref-type="other"}; [Marsh *et al*, 1996](#bib23){ref-type="other"}, [2003](#bib24){ref-type="other"}; [Romei *et al*, 1996](#bib28){ref-type="other"}; [Wohllk *et al*, 1996](#bib39){ref-type="other"}; [Bugalho *et al*, 1997](#bib5){ref-type="other"}; [Scurini *et al*, 1998](#bib33){ref-type="other"}; [Shan *et al*, 1998](#bib34){ref-type="other"}; [Uchino *et al*, 1998](#bib37){ref-type="other"}, [1999](#bib38){ref-type="other"}; [Bockhorn *et al*, 1999](#bib3){ref-type="other"}; [Dvorakova *et al*, 2008](#bib10){ref-type="other"}; [Elisei *et al*, 2008](#bib11){ref-type="other"}). Met918Thr *RET* mutation is the most common somatic mutation in sporadic forms of MTC, and its detection rate varies greatly (5--66%) in the published literature ([Zedenius *et al*, 1994](#bib41){ref-type="other"}; [Marsh *et al*, 1996](#bib23){ref-type="other"}; [Romei *et al*, 1996](#bib28){ref-type="other"}; [Wohllk *et al*, 1996](#bib39){ref-type="other"}; [Bugalho *et al*, 1997](#bib5){ref-type="other"}; [Scurini *et al*, 1998](#bib33){ref-type="other"}; [Uchino *et al*, 1998](#bib37){ref-type="other"}, [1999](#bib38){ref-type="other"}; [Dvorakova *et al*, 2008](#bib10){ref-type="other"}; [Elisei *et al*, 2008](#bib11){ref-type="other"}). However, in some of these studies, the authors have screened sporadic MTC for only a few specific mutations, mostly in codon 918 ([Hofstra *et al*, 1994](#bib16){ref-type="other"}; [Shan *et al*, 1998](#bib34){ref-type="other"}; [Bockhorn *et al*, 1999](#bib3){ref-type="other"}; [Marsh *et al*, 2003](#bib24){ref-type="other"}). Therefore, the number of exons screened, as well as the sizes of the analysed series, may explain some of the reported differences in the prevalence of *RET* mutations in sporadic MTC. In addition, ethnic or environmental factors, differences in detection or in sampling methods may also account for the reported differences ([Uchino *et al*, 1998](#bib37){ref-type="other"}; [Dvorakova *et al*, 2008](#bib10){ref-type="other"}). In some cohorts, besides the Met918Thr mutation, other somatic mutations were also detected, at a lower frequency in exons 10, 11, 12, 13 and 15 ([Bugalho *et al*, 1997](#bib5){ref-type="other"}; [Scurini *et al*, 1998](#bib33){ref-type="other"}; [Uchino *et al*, 1999](#bib38){ref-type="other"}).

The major somatic mutation (Met918Thr) localised in the tyrosine kinase domain in exon 16 of *RET* ([Marini *et al*, 2006](#bib22){ref-type="other"}) has been associated to a worse clinical outcome in sporadic MTC when compared with tumours that did not harbour this mutation ([Zedenius *et al*, 1994](#bib41){ref-type="other"}, [1995](#bib40){ref-type="other"}; [Wohllk *et al*, 1996](#bib39){ref-type="other"}; [Schilling *et al*, 2001](#bib31){ref-type="other"}).

Several reports have presented contradictory results concerning the ploidy pattern in MTC. [Schröder *et al* (1988)](#bib32){ref-type="other"} found that most MTC have a diploid DNA pattern, and that a benign disease course was twice as frequent in patients with diploid tumours compared with aneuploid tumours. Conversely, the results presented by [Lindsay (1970)](#bib21){ref-type="other"} seemed to be more consistent with aneuploidy in MTC.

In this study, we carried out a comprehensive analysis of exons 5, 8 and 10--16 of *RET* to evaluate the prevalence of somatic mutations in a series of fifty-one sporadic MTC and to correlate with clinicopathological characteristics of the patients, including tumour ploidy pattern.

Materials and methods
=====================

Patients
--------

A total of fifty-two unrelated patients with MTC without family history of the disease were studied for *RET* mutations. A detailed personal history was obtained from all patients. All individuals were of Caucasian origin (34 females and 18 males). Each patient underwent total thyroidectomy, with the exception of two patients who were submitted to partial thyroidectomy. The diagnosis of MTC was confirmed by histopathology of the surgically removed tumours. The Tumour-Node-Metastases (TNM) classification of all tumour specimens was carried out after the criteria described in the WHO classification of thyroid tumours ([DeLellis *et al*, 2004](#bib8){ref-type="other"}). Stage grouping was addressed according to the TNM classification ([Sobin and Wittekind, 2002](#bib36){ref-type="other"}), namely, stage I (T1N0M0), stage II (T2N0M0), stage III (T3N0M0 or T1-T3N1aM0) and stage IV (T1-T3N1bM0, T4N0-N1M0 or T1-T4N0-N1M1).

The number of truly sporadic MTC patients was reduced to fifty-one, as a germline mutation was found in one case.

Eight of the fifty-one cases ([Table 1](#tbl1){ref-type="table"}, patients 10, 15, 34, 35, 36, 38, 43 and 45) were earlier published by our group ([Bugalho *et al*, 1997](#bib5){ref-type="other"}, [2000](#bib4){ref-type="other"}).

This study was carried out following guidelines approved by the local institution ethical board.

DNA flow cytometry
------------------

DNA flow cytometry analysis was carried out on paraffin-embedded material, according to the method of [Hedley *et al* (1983)](#bib15){ref-type="other"}, with slight modifications ([André *et al*, 2007](#bib1){ref-type="other"}).

Serum calcitonin measurements
-----------------------------

Serum calcitonin (CT) levels were determined using a solid-phase, enzyme-labelled, two-site chemiluminescent immunoenzymatic assay (Immulite 2000 Calcitonin, Siemens Medical Solutions Diagnostic Ltd., Llanberis, Gwynedd, UK) with the Immulite 2000 Automated Analyser (Siemens Medical Solutions Diagnostic Ltd.). CT values \<2.0 ng l^--1^ were regarded as undetectable.

*RET* variant analysis
----------------------

DNA was extracted from tumour samples frozen in liquid nitrogen (*n*=47) following standard protocols. Otherwise, DNA was isolated from formalin-fixed paraffin-embedded tumour tissues (*n*=5), as described earlier ([Imyanitov *et al*, 2001](#bib18){ref-type="other"}). Exons 5, 8 and 10 through 16 of *RET* were amplified by PCR. Sequences of the oligonucleotide primers and amplification conditions are available on request. Sequencing was carried out in both sense and antisense directions, using the same primers as for PCR amplification and the ABI PRISM BigDye Terminator version 1.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA), in an automated DNA sequencer (ABI PRISM 310 Genetic Analyser, Applied Biosystems). All the mutations identified were confirmed by two independent experiments (restriction enzyme analysis, or repeated sequence analysis). To support somatic origin of the mutations, constitutional DNA from peripheral blood or non-tumourous tissue from the same patient was also analysed.

Statistical analysis
--------------------

The statistical analysis was accomplished using GraphPad Prism version 4.0 statistical software (GraphPad Software Inc., San Diego, CA, USA) and SPSS 13.0 for Windows (SPSS Inc., Chicago, IL, USA). Values were expressed as mean±s.e.m. The *χ*^2^ or Fisher\'s exact tests, and one-way analysis of variance or Kruskal--Wallis test were used according to the studied variables. Survival curves were analysed using the Kaplan--Meier method, and the statistical significance was assessed by the logrank test. Values of *P*\<0.05 were considered statistically significant.

Results
=======

Genetic analysis
----------------

One out of the fifty-two (1.9%) cases of clinically apparently sporadic MTC carried a new germline mutation (Cys515Trp) located in exon 8 (manuscript under preparation). This case was excluded from further analysis.

In the remaining fifty-one sporadic MTC cases, thirty-three (64.7%) had mutations in *RET* exons 10, 11, 15 and 16 ([Table 2](#tbl2){ref-type="table"}). The absence of these mutations in the constitutional DNA excluded a germline origin.

Among the *RET*-positive cases, exon 16 was the most frequently affected (60.6%) by the same specific Met918Thr mutation, followed by exon 11 (21.2%). *RET* mutations were also detected in exons 10 (9.1%) and 15 (9.1%). In the present series, two novel *RET* mutations (Cys630Gly and c.1881del18) located at exon 11 were identified. The novel Cys630Gly variant creates a restriction site for the enzyme *Bsr*I, facilitating its independent confirmation (data not shown). The other novel variant (c.1881del18) is expected to lead to the replacement of seven amino acid residues by a glutamic acid residue. In this case, PCR amplification originated two fragments: the expected wild-type product (322 bp) and a smaller mutant product (304 bp), allowing the independent sequencing of both alleles (data not shown). Together with this mutation, and in the same allele, an unreported heterozygous nucleotide change in codon 634 (TGC to TGT) that does not predict an amino acid alteration (Cys to Cys) was found (data not shown).

In the MTC tissue of patient 51, with a Cys618Arg mutation ([Table 1](#tbl1){ref-type="table"}), the wild-type allele was not detected. The finding of allelic loss at flanking markers D10S141 and ZNF22 showed hemizygosity for this mutation (data not shown).

No mutations were identified in the other analysed exons, namely, exons 5, 8, 12, 13 or 14 ([Table 2](#tbl2){ref-type="table"}).

Forty-four (86.3%) tumours displayed a diploid DNA content and seven (13.7%) were aneuploid. No correlation between the presence or type of *RET* mutation and the ploidy pattern was observed ([Table 3](#tbl3){ref-type="table"}).

Clinical evaluation
-------------------

[Table 1](#tbl1){ref-type="table"} describes the clinical and pathological data of the fifty-one patients with sporadic MTC.

In the thirty-three MTC patients (19 females and 14 males) carrying somatic *RET* mutations, the mean age at surgery and mean follow-up time were 52.9 years (median 55, range 26--71) and 94.8 months (median 100, range 4--303), respectively. Lymph node and distant metastases were present in 23/33 (69.7%) and 11/31 (35.5%) cases, respectively. According to the TNM classification, four patients (12.1%) had stage I disease, three (9.1%) had stage II, two (6.1%) had stage III and twenty-four (72.7%) had stage IV. At the time of the last clinical screening, nine patients (29.0%) were free of disease, and twenty-two (71.0%) were non-disease free (seven of them were deceased from MTC). The status at last control from two patients was not available. Among the twenty-two patients with persistent disease, ten (47.6%) showed a biochemical persistence of the disease with detectable levels of serum CT, but no evidence of distant metastases, whereas eleven patients (52.4%) were affected by metastatic disease. Clinical data from one case were not available.

As regard to the eighteen MTC patients (14 females and 4 males) without somatic *RET* mutation, the mean age at surgery and mean follow-up were 55.8 years (median 59.5, range 27--82) and 90.8 months (median 73.5, range 0.6--252), respectively. Lymph node and distant metastases were present in 11/18 (61.1%) and 3/18 (16.7%) cases, respectively. Three patients (16.7%) had stage I disease, four (22.2%) had stage II, one (5.6%) had stage III and ten (55.6%) had stage IV, at last control. At the time of the last clinical screening, eight patients (44.4%) were free of disease and ten (55.6%) were non-disease free (two of them were deceased from MTC). Among the ten patients with persistent disease, six (66.7%) showed a biochemical persistence of the disease but no evidence of distant metastases, whereas three patients (33.3%) were affected by metastatic disease. Biochemical data from one case were not available.

For all these clinical and pathological data, there was no statistically significant difference between *RET*-positive and *RET*-negative patients. When the survival curves of *RET*-positive and *RET*-negative MTC patients were compared, a lower percentage of surviving patients was observed in the group with the somatic *RET* mutation, although not statistically significant (data not shown).

As the more aggressive *RET* mutations are in codons 883 and 918, which are classified as level 3 ([de Groot *et al*, 2006](#bib7){ref-type="other"}), we compared clinical data of somatic Met918Thr and Ala883Phe *RET* mutation cases (group 1; *n*=23, 45.1%) *vs* cases carrying other somatic *RET* mutations (group 2; *n*=10, 19.6%), or having no *RET* mutation (group 3; *n*=18, 35.3%) ([Table 3](#tbl3){ref-type="table"}).

Group 1 cases (compared with group 2) had higher prevalence of lymph node metastases (*P*=0.0051), higher number of positive lymph nodes (*P*=0.0017), were more frequently multifocal (*P*=0.037) and had more often persistent disease at last control (*P*=0.0242). Moreover, group 1 was more frequently associated with detectable serum CT levels at the last screening (*P*=0.0119), as well as with stage IV (*P*=0.0145; *vs* stages I--III), than groups 2 and 3.

Serum CT levels at the last control were highest in group 1 (37521±13818 ng l^--1^), intermediate in group 3 (11501±6028 ng l^--1^) and lowest in group 2 (651.2±624.7 ng l^--1^). However, the difference was only statistically significant between group 1 and group 2 patients (Kruskal--Wallis test plus Dunn\'s multiple comparison test, *P*=0.0035). Also, the serum CT levels after surgery were higher in group 1 than in the other groups, but the difference did not reach statistical significance (group 1: 8096±3517 ng l^--1^, group 3: 1135±856.5 ng l^--1^, group 2: 206.4±132.2 ng l^--1^; Kruskal--Wallis test, *P*=0.0628).

Although not statistically significant, there was a trend for a higher prevalence of distant metastases in group 1.

There was no statistical significant difference between patients of the different groups regarding the remaining clinicopathological characteristics ([Table 3](#tbl3){ref-type="table"}). Furthermore, when the survival curves of MTC patients from the three groups were evaluated, no significant differences were observed between each group (data not shown).

Discussion
==========

Medullary thyroid carcinoma is clinically diagnosed as sporadic when the patient does not present other endocrine tumours, and when no other cases of MTC, pheochromocytoma or parathyroid disease are identified in the patient\'s family. However, only the exclusion of germline mutations in the *RET* proto-oncogene allows a definitive diagnosis of sporadic MTC.

The herein reported cohort is one of the largest single-country studies. Fifty-one sporadic MTC were analysed and somatic mutations were found in thirty-three (64.7%) cases. Two novel mutations were identified in exon 11 of the *RET* proto-oncogene, in two sporadic MTC cases: a heterozygous point mutation at codon 630 (Cys630Gly), and a 18 bp deletion at nucleotide c.1881 associated in the same allele with a silent nucleotide substitution at codon 634 (Cys634Cys). Both mutations are located in the cysteine-rich domain coding sequence, which, when mutated, has been shown to constitutively activate RET ([Santoro *et al*, 1995](#bib29){ref-type="other"}, [2002](#bib30){ref-type="other"}).

In this study, eight earlier described missense changes in *RET* were detected in exons 10, 11, 15 and 16. In accordance with other studies, the most common mutation was Met918Thr with a detection rate of 39.2%, which represents 60.6% of all detected mutations. In one case, loss of heterozygosity at *RET* flanking microsatellite markers was detected, showing hemizygosity for a sporadic missense mutation (Cys618Arg), a rare genetic event that has been reported earlier for other *RET* mutations ([Jindrichova *et al*, 2003](#bib20){ref-type="other"}; [Dvoráková *et al*, 2006](#bib9){ref-type="other"}).

As *RET* mutations other than Met918Thr are rare, most of the reported series did not compare the clinicopathological characteristics of Met918Thr *vs* other *RET* mutations ([Dvorakova *et al*, 2008](#bib10){ref-type="other"}; [Elisei *et al*, 2008](#bib11){ref-type="other"}). In our study, 13/51 (25.5%) cases had a *RET* mutation other than Met918Thr, which allowed such comparison. On the basis of the recent literature, *RET* mutations have been stratified into three risk levels, regarding the predisposition to originate MTC, as well as their *in vitro* transforming activity. Patients with germline mutations in *RET* codons 883 (exon 15) and 918 (exon 16), for which thyroidectomy is recommended at an early age, have the highest risk for the early development and the most aggressive MTC growth ([Evans *et al*, 2007](#bib13){ref-type="other"}). Likewise, these two mutations (which are considered as level 3) have the highest *in vitro* transforming activity. Therefore, in this study, cases with Ala883Phe or Met918Thr mutations were analysed in the same group (group 1), and compared with cases with other somatic *RET* mutations (group 2) and cases with no *RET* mutation (group 3).

A statistically significant correlation was shown between group 1 and the presence of lymph node metastases, as well as the number of positive lymph nodes at the time of surgery, multifocality and a non-disease free status, compared with group 2. This correlation may account for the significantly higher frequency of patients from group 1 in stage IV and with detectable serum CT level at last control, compared with groups 2 and 3, and also for the significantly increased levels of serum CT at the last control in group 1 cases in comparison with group 2. Furthermore, such correlation supports the hypothesis that mutations in *RET* exons 15 and 16 are related to a more aggressive behaviour of MTC. This could be explained by an earlier dissemination of Met918Thr and Ala883Phe cases to lymph nodes ([Table 3](#tbl3){ref-type="table"}). Indeed, 26.1% of MTC cases came to clinical attention because of lymph nodes in group 1, whereas this occurred in only 0.0% and 11.8% of the cases in groups 2 and 3, respectively.

The results presented in [Table 3](#tbl3){ref-type="table"} show a trend towards the stratification of the three groups of sporadic MTC patients into risk levels on the basis of the statistically significant clinicopathological characteristics. Group 1 patients are at the highest risk for aggressive MTC, followed by group 3 at intermediate risk, and group 2 patients, which present the lowest risk for a worse clinical outcome. Therefore, our study shows that *RET* mutations in exons 15 and 16 are associated with a more aggressive behaviour of sporadic MTC than other *RET* mutations, as it has been shown *in vitro*, as well as in the hereditary variants of MTC.

Taken together, these results suggest that the screening of *RET* somatic mutations may be helpful in the management of patients with MTC, according to the presence and type of *RET* somatic mutation.

The authors are indebted to the kind collaboration of Dra. Alexandra Mayer. We also express our gratitude to the staff of Serviço de Anatomia Patológica from the Instituto Português de Oncologia de Lisboa Francisco Gentil E.P.E., for their skilful assistance. This research did not receive any specific grant from any funding agency in the public, commercial or not-for-profit sector.

**Conflict of interest**

The authors declare no conflict of interest.

###### 

Clinical and genetic findings in fifty-one patients with sporadic MTC

  **Patient no.**   **Sex**   ***RET* somatic mutation**   **MTC presentation**    **Age at surgery (years)**   **Tumour size^a^ (cm)**   **Post-oper. serum CT (ng l^--1^)**   **Serum CT at last control (ng l^--1^)**  **TNM classification at last control**    **No. of positive lymph nodes**   **Overall survival (months)**   **Disease free survival (months)**   **Status at last control**   **Extragl. ext.**   **Vasc. inv.**   **Multif.**  **Ploidy pattern**
  ----------------- --------- ---------------------------- ---------------------- ---------------------------- ------------------------- ------------------------------------- ------------------------------------------ ---------------------------------------- --------------------------------- ------------------------------- ------------------------------------ ---------------------------- ------------------- ---------------- ------------- --------------------
  1                 F         **c.1881del18+ Cys634Cys**   TN                                  50                         1.5                            19.4                                    132.0                    T1N1bM0                                                  5                               149                                0                               NDF                      No                 NA             No       D
  2                 F         Neg                          TN                                  50                          2                           Undetect.                               Undetect.                  T1N0M0                                                   0                               172                               172                               DF                      No                 No             No       D
  3                 M         **Cys630Gly**                TN                                  71                          6                            1290.0                                   5647.0                   T4aN0MX                                                  0                               74                                 0                               NDF                      Yes               Yes             No       D
  4                 M         Neg                          TN                                  69                         12                             449.8                                  53341.0                   T4bN1aM0                                                 2                               196                                0                               NDF                      Yes               Yes             No       D
  5                 M         Met918Thr                    TN+LN                               69                          7                            1610.0                                  14594.0                   T4bmN1bM1                                               19                              Dec/9                               0                               NDF                      Yes               Yes             Yes      D
  6                 F         Met918Thr                    TN+LN                               59                         3.5                            869.0                                  16209.0                   T2N1bM1                                                  7                               167                                0                               NDF                      No                 NA             No       D
  7                 F         Met918Thr                    TN                                  39                          5                              2.2                                    9361.0                   T3N1bM0                                                 20                               303                                24                              NDF                      NA                 NA             No       D
  8                 F         Neg                          LN                                  77                         3.5                             NA                                       NA                     T4aN1bM0                                                18                             18 days                              0                               NDF                      Yes                NA             No       D
  9                 M         Neg                          TN+LN                               59                          7                             265.0                                   1162.0                   T4aN1bM1                                                 2                             Dec/35                               0                               NDF                      Yes               Yes             No       A (1.86)
  10                M         Met918Thr                    LN                                  58                         3.5                             NA                                       NA                     T4amN1bM0                                              \>10                               0                                 0                                NA                      Yes               Yes             Yes      D
  11                F         Neg                          LN                                  46                         10                             418.2                                  88512.0                   T4aN1bM1                                                17                             Dec/29                               0                               NDF                      Yes                NA             No       D
  12                F         Ala883Phe                    TN+LN                               59                         4.5                           16493.0                                 158014.0                  T4amN1bM1                                              \>10                            Dec/32                               0                               NDF                      Yes               Yes             Yes      D
  13                F         Met918Thr                    TN                                  53                         2.1                            68.9                                   97706.0                   T2N1aM1                                                  0                             Dec/12                               0                               NDF                      No                 NA             No       D
  14                F         Met918Thr                    TN                                  49                          4                             86.6                                    833.0                    T2N1bM0                                                 18                               143                                0                               NDF                      No                Yes             No       D
  15                F         Cys634Arg                    TN                                  67                         3.5                            179.4                                    81.7                    T2N0M0                                                   0                               141                                0                               NDF                      No                Yes             No       D
  16                F         Neg                          TN                                  60                         5.5                            261.0                                 Undetect.                  T3N1aM0                                                  1                               79                                 79                               DF                      No                 No             No       D
  17                F         Met918Thr                    TN+LN                               26                          3                              NA                                       NA                     T2mN1bMX                                                18                               NA                                 NA                               NA                      No                Yes             Yes      D
  18                M         Cys620Ser                    TN                                  31                         1.8                             7.8                                  Undetect.                  T1N0M0                                                   0                               124                               124                               DF                      No                 No             No       D
  19                M         Ala883Phe                    TN+LN                               55                          5                             110.5                                  33800.0                   T3mN1bM1                                                10                             Dec/85                               0                               NDF                      No                Yes             Yes      D
  20                F         Neg                          TN                                  72                         8.5                            12.3                                    823.0                    T3mN1bM0                                                12                               49                                 0                               NDF                      No                 NA             Yes      D
  21                M         Met918Thr                    TN+LN                               49                          2                             141.0                                   3999.0                   T4aN1bM0                                                 7                               56                                 0                               NDF                      Yes                NA             No       A (1.65)
  22                M         Met918Thr                    TN                                  71                         4.5                           8525.0                                  14584.0                   T4amN1bM0                                               37                               11                                 0                               NDF                      Yes               Yes             Yes      D
  23                F         Neg                          TN                                  27                         NA                              NA                                      78.3                    TXN1bM0                                                 NA                               252                                0                               NDF                      NA                 NA             NA       D
  24                M         Cys620Arg                    TN                                  70                         4.5                             6.5                                  Undetect.                  T3N1bM0                                                  3                               61                                 61                               DF                      No                 NA             NA       A (1.93)
  25                F         Met918Thr                    TN+LN                               66                          4                           Undetect.                               Undetect.                  T2N1bM0                                                  3                               70                                 70                               DF                      No                 No             No       D
  26^b^             F         Neg                          TN                                  47                         3.5                          Undetect.                               Undetect.                  T2N0M0                                                   0                               72                                 72                               DF                      No                 No             No       A (1.95)
  27                F         Met918Thr                    TN                                  50                         1.7                            84.8                                     25.9                    T4aN1aM0                                                 6                               45                                 0                               NDF                      Yes               Yes             NA       D
  28                F         Neg                          TN                                  61                          3                           Undetect.                               Undetect.                  T2N0M0                                                   0                               48                                 48                               DF                      No                 No             No       D
  29                M         Met918Thr                    LN                                  43                         2.5                           60307.0                                 103334.0                  T2N1bM1                                                 30                               41                                 0                               NDF                      No                 No             No       D
  30                F         Cys634Arg                    TN                                  71                         1.6                          Undetect.                               Undetect.                  T1N0M0                                                   0                               46                                 46                               DF                      No                 NA             No       D
  31                F         Cys630Arg                    TN                                  67                         4.3                          Undetect.                               Undetect.                  T3N0M0                                                   0                               113                               113                               DF                      No                 No             No       A (1.97)
  32                F         Met918Thr                    LN                                  60                         0.8                           1234.0                                   1205.0                   T1N1bM0                                                  8                               103                                0                               NDF                      No                 NA             No       D
  33                F         Neg                          TN                                  61                         3.5                            47.5                                  Undetect.                  T2N0M0                                                   0                               177                               177                               DF                      No                 No             No       D
  34                F         Cys630Arg                    TN                                  62                         2.5                            10.4                                  Undetect.                  T2N0M0                                                   0                               178                               178                               DF                      No                 No             No       D
  35                M         Met918Thr                    TN                                  67                          3                              8.5                                   15725.0                   T2mN1bM0                                                 8                               146                                0                               NDF                      No                 No             Yes      D
  36                M         Met918Thr                    TN                                  29                          5                             36.4                                  Undetect.                  T3N0M0                                                   0                               135                               135                               DF                      No                Yes             No       A (1.83)
  37                F         Neg                          TN+LN                               77                          8                            2582.0                                  17732.0                   T3N1bM1                                                  8                               119                                0                               NDF                      No                Yes             No       D
  38                F         Met918Thr                    TN                                  57                         2.5                             8.8                                     10.6                    T2N0M0                                                   0                               132                               132                              NDF                      No                 No             No       D
  39                F         Met918Thr                    TN                                  32                         1.7                          Undetect.                               Undetect.                  T1N0M0                                                   0                               121                               121                               DF                      No                 No             No       D
  40                F         Met918Thr                    LN                                  51                         2.3                           1970.0                                   9953.0                   T4amN1bM1                                               10                               21                                 0                               NDF                      Yes                No             Yes      A (1.86)
  41^b^             F         Neg                          TN                                  27                          3                           Undetect.                               Undetect.                  T2N0M0                                                   0                               100                               100                               DF                      No                Yes             No       D
  42                F         Neg                          NA                                  82                         1.2                          Undetect.                               Undetect.                  T1N0M0                                                   0                               75                                 75                               DF                      No                 No             No       D
  43                M         Met918Thr                    LN                                  29                         1.5                           36720.0                                 245000.0                  T1mN1bM1                                                 4                             Dec/100                              0                               NDF                      No                 No             Yes      D
  44                M         Neg                          TN                                  40                          2                             268.0                                    46.9                    T2N1bM0                                                  3                               178                                0                               NDF                      No                Yes             No       D
  45                M         Val882Val+Ala883Phe          LN                                  35                         10                            34342.0                                 42694.0                   T4aN1bM1                                                27                             Dec/94                               0                               NDF                      Yes                No             No       D
  46                F         Cys634Tyr                    TN                                  46                          2                           Undetect.                               Undetect.                  T1N0M0                                                   0                               123                               123                               DF                      No                 No             No       D
  47                M         Met918Thr                    TN+LN                               44                         3.5                           7400.0                                  20884.0                   T2N1bM1                                                \>12                              101                                0                               NDF                      No                 NA             No       D
  48                F         Neg                          TN                                  42                         0.9                          Undetect.                               Undetect.                  T1N0M0                                                   0                               16                                 16                               DF                      No                 No             No       D
  49                F         Neg                          TN+LN                               46                          1                             89.0                                    128.0                    T3mN1bM0                                                10                               18                                 0                               NDF                      Yes               Yes             Yes      D
  50                M         Neg                          TN+LN                               61                          5                            13762.0                                 33687.0                   T4amN1bM0                                               16                               18                                 0                               NDF                      Yes               Yes             Yes      D
  51                F         Cys618Arg                    TN+LN                               61                         10                             550.0                                     NA                     T4aN1bM1                                                 4                              Dec/4                               0                               NDF                      Yes                NA             No       D

Abbreviations: A=aneuploid; CT=calcitonin; D=diploid; Dec=deceased from MTC; DF=disease free; Extragl. ext.=extraglandular extension; F=female; LN=lymph node; M=male; MTC=medullary thyroid carcinomas; Multif.=multifocality; NA=not available; NDF=non-disease free; Neg=negative for *RET* mutations; No.=number; Post-oper.=post-operative; *RET*=*RE*arranged during *T*ransfection; TN=thyroid nodule; TNM=Tumour-Node-Metastases; Undetect.=undetectable; Vasc. inv.=vascular invasion.

(the biggest).

Partial thyroidectomy.

###### 

*RET* mutations identified in sporadic MTC cases

  **Exon**   **Type of alteration**                      **Number of patients**   **% of patients carrying a *RET* somatic mutation**
  ---------- ------------------------------------------- ------------------------ -----------------------------------------------------
  10         TGC\>CGC (Cys618Arg)^a^                     1                        9.1%
             TGC\>CGC (Cys620Arg)                        1                         
             TGC\>TCC (Cys620Ser)                        1                         
  11         TGC\>CGC (Cys630Arg)                        2                        21.2%
             **TGC\>GGC (Cys630Gly)**                    1                         
             TGC\>CGC (Cys634Arg)                        2                         
             TGC\>TAC (Cys634Tyr)                        1                         
             **c.1881del18+ TGC\>TGT (Cys634Cys)**       1                         
  15         GCT\>TTT(Ala883Phe)+ GTA\>GTT (Val882Val)   1                        9.1%
             GCT\>TTT (Ala883Phe)                        2                         
  16         ATG\>ACG (Met918Thr)                        20                       60.6%

Abbreviations: MTC=medullary thyroid carcinomas; *RET*=*RE*arranged during *T*ransfection.

This mutation was in the hemizygous status.

Mutations were present only in tumour DNA.

The two novel *RET* proto-oncogene variants are represented in bold.

###### 

Clinical and pathological characteristics of patients with Met918Thr and Ala883Phe (group 1) *vs* other *RET* mutations (group 2) or no mutation (group 3) in sporadic MTC

  **Characteristics**                             **Group 1 Met918Thr and Ala883Phe *RET* mutation (*n*=23, 45.1%)**   **Group 2 Other *RET* mutation (*n*=10, 19.6%)**   **Group 3 No *RET* mutation (*n*=18, 35.3%)**   ***P*-value**
  ----------------------------------------------- -------------------------------------------------------------------- -------------------------------------------------- ----------------------------------------------- ---------------------
  *Sex*                                           0.2175^a^                                                                                                                                                               
   Female                                         52.2% (12/23)                                                        70.0% (7/10)                                       77.8% (14/18)                                    
   Male                                           47.8% (11/23)                                                        30.0% (3/10)                                       22.2% (4/18)                                     
                                                                                                                                                                                                                           
  *MTC presentation*                              0.099^b^                                                                                                                                                                
   Thyroid nodule                                 39.1% (9/23)                                                         90.0% (9/10)                                       64.7% (11/17)                                    
   Lymph node                                     26.1% (6/23)                                                         0.0% (0/10)                                        11.8% (2/17)                                     
   Thyroid nodule and lymph node                  34.8% (8/23)                                                         10.0% (1/10)                                       23.5% (4/17)                                     
  *Age at surgery (years), mean±s.e.m.*           50.00±2.80                                                           59.60±4.19                                         55.78±3.85                                      0.1835^c^
  *Tumour size (cm), mean±s.e.m.*                 3.59±0.42                                                            3.77±0.84                                          4.68±0.81                                       0.4240^c^
                                                                                                                                                                                                                           
  *Post-operative serum calcitonin*               0.132^b^                                                                                                                                                                
   Undetectable                                   9.5% (2/21)                                                          30.0% (3/10)                                       37.5% (6/16)                                     
   Detectable                                     90.5% (19/21)                                                        70.0% (7/10)                                       62.5% (10/16)                                    
                                                                                                                                                                                                                           
  *Serum calcitonin at last control*              ***0.0119***^**a**^                                                                                                                                                     
   Undetectable                                   14.3% (3/21)                                                         66.7% (6/9)                                        47.1% (8/17)                                     
   Detectable                                     85.7% (18/21)                                                        33.3% (3/9)                                        52.9% (9/17)                                     
                                                                                                                                                                                                                           
  *T categories*                                  0.664^b^                                                                                                                                                                
   T1                                             13.0% (3/23)                                                         40.0% (4/10)                                       17.6% (3/17)                                     
   T2                                             39.1% (9/23)                                                         20.0% (2/10)                                       29.4% (5/17)                                     
   T3                                             13.0% (3/23)                                                         20.0% (2/10)                                       23.5% (4/17)                                     
   T4                                             34.8% (8/23)                                                         20.0% (2/10)                                       29.4% (5/17)                                     
                                                                                                                                                                                                                           
  *T categories grouping*                         0.6944^a^                                                                                                                                                               
   T1--T3                                         65.2% (15/23)                                                        80.0% (8/10)                                       70.6% (12/17)                                    
   T4                                             34.8% (8/23)                                                         20.0% (2/10)                                       29.4% (5/17)                                     
                                                                                                                                                                                                                           
  *Lymph node metastases*                         ***0.0051***^**a**^                                                                                                                                                     
   N1                                             87.0% (20/23)                                                        30.0% (3/10)                                       61.1% (11/18)                                    
   N0                                             13.0% (3/23)                                                         70.0% (7/10)                                       38.9% (7/18)                                     
                                                                                                                                                                                                                           
  *Distant metastases*                            0.0588^a^                                                                                                                                                               
   M1                                             45.5% (10/22)                                                        11.1% (1/9)                                        16.7% (3/18)                                     
   M0                                             54.5% (12/22)                                                        88.9% (8/9)                                        83.3% (15/18)                                    
  *Presence of extraglandular extension*          36.4% (8/22)                                                         20.0% (2/10)                                       35.3% (6/17)                                    0.6314^a^
  *Presence of vascular invasion*                 52.9% (9/17)                                                         33.3% (2/6)                                        50.0% (7/14)                                    0.823^b^
  *Presence of multifocality*                     40.9% (9/22)                                                         0.0% (0/9)                                         17.6% (3/17)                                    ***0.037***^**b**^
                                                                                                                                                                                                                           
  *Ploidy pattern*                                0.758^b^                                                                                                                                                                
   Diploid                                        87.0% (20/23)                                                        80.0% (8/10)                                       88.9% (16/18)                                    
   Aneuploid                                      13.0% (3/23)                                                         20.0% (2/10)                                       11.1% (2/18)                                     
                                                                                                                                                                                                                           
  *Stage*                                         0.065^b^                                                                                                                                                                
   I                                              4.3% (1/23)                                                          30.0% (3/10)                                       16.7% (3/18)                                     
   II                                             4.3% (1/23)                                                          20.0% (2/10)                                       22.2% (4/18)                                     
   III                                            4.3% (1/23)                                                          10.0% (1/10)                                       5.6% (1/18)                                      
   IV                                             87.0% (20/23)                                                        40.0% (4/10)                                       55.6% (10/18)                                    
                                                                                                                                                                                                                           
  *Stage grouping*                                ***0.0145***^**a**^                                                                                                                                                     
   I--III                                         13.0% (3/23)                                                         60.0% (6/10)                                       44.4% (8/18)                                     
   IV                                             87.0% (20/23)                                                        40.0% (4/10)                                       55.6% (10/18)                                    
  *Number of positive lymph nodes, mean±s.e.m.*   11.48±2.09                                                           1.20±0.63                                          5.24±1.64                                       ***0.0017***^**d**^
  *Follow-up (months), mean±s.e.m.*               91.8±15.1                                                            101.3±16.9                                         90.8±17.6                                       0.9180^c^
                                                                                                                                                                                                                           
  *Status at last control*                        ***0.0242***^**a**^                                                                                                                                                     
   Disease free                                   14.3% (3/21)                                                         60.0% (6/10)                                       44.4% (8/18)                                     
   Non-disease free                               85.7% (18/21)                                                        40.0% (4/10)                                       55.6% (10/18)                                    

Abbreviations: MTC=medullary thyroid carcinomas; *RET*=*RE*arranged during *T*ransfection.

*χ*^2^-test,

Fisher\'s exact test,

One-way analysis of variance and

Kruskal--Wallis test.

*P-*values in *italics* and bold are statistically significant.
